France’s Gemme Unveils Three-Point Plan To Bolster Biosimilars
As Biosimilar Penetration Falls Short Of Government’s ‘Ambitious’ Target
Fresh impetus is needed to help biosimilars achieve their full potential in France, according to off-patent industry association Gemme. The organization has unveiled a three-point plan to bolster the sector that includes proposals to allow pharmacists to substitute biosimilars for brand prescriptions under certain circumstances.
You may also be interested in...
Stakeholders Surprised As French Biosimilar Substitution Changes Tack
The latest step towards biosimilar substitution taken by the French authorities has left stakeholders baffled by an unexplained shift in approach, including a change to the specific biologic molecules that have been selected as eligible for substitution.
French Body Favors Pharmacy Substitution For Biosimilars
French off-patent association Gemme has made a bold show of support for pharmacy-level biosimilar substitution in a position statement published by the industry body. However, the proposals run against the views of broader European industry association Medicines for Europe and come against the backdrop of recently-adopted French legislation that ensures doctors will be involved in biologic substitution.
France sets 80% biosimilar goal
Agoal of 80% biosimilar penetration within their individual markets by 2022 has been set by France’s government, as part of a broader healthcare strategy set out by the health ministry for the next five years. This will be achieved by promoting biosimilars “which present the same efficacy, the same quality and the same safety as the biological reference product”, according to the proposals. Local medicines agency ANSM recently introduced 11 ‘similar biologic groups’ designating equivalence categories for biosimilars, alongside guidance that advises prescribing biosimilars at any point during a course of treatment and favours lowerpriced alternatives (Generics bulletin, 10 November 2017, page 11).